Abivax S.A.

The stock is still in a damaged intermediate trend, trading below its 200-day moving average after a sharp run from the 52-week low. The longer-term setup remains volatile and speculative, with the share price far from the 52-week high and prone to large swings around clinical and analyst headlines.

Wall Street stays constructive overall, with a Buy consensus and a $123.43 average target versus a $132 median. The recent pattern is mixed but still supportive: several firms cut targets in early June, yet the broader rating mix remains 10 Buys and 2 Holds with no Sell ratings.

The next print follows a choppy beat/miss record, with 4 beats in the last 7 quarters. Estimates still point to losses, with next-year EPS at -3.295 versus TTM EPS of -5.23, so shareholders should watch for execution on the path to narrowing losses rather than near-term profitability.

No notable insider activity. The recent transactions table is empty, so there is no discretionary buying or selling signal to read through.

Profitability remains weak, but the balance sheet is strong. Gross margin is 100.0%, while operating margin is -41.8% and ROE is -157.1%; cash and equivalents of $530.2 million exceed total debt of $45.9 million, leaving net cash of $484.3 million.

As a clinical-stage biotech, ABVX screens as a higher-risk, pipeline-driven name rather than a cash-flow compounder. The valuation still reflects that profile, with a negative P/E and a market cap of about $6.39 billion despite no current earnings power.